Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks
The Journal of Infectious Diseases · 03.10.2023 · 228 (7) · 907-918
DOI: 10.1093/infdis/jiad292 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 27.07.2023. Verfasst von Lisa Jörimann und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich. Hauptthemen laut MEDLINE: HIV-1, HIV Infections. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swiss National Science Foundation, Clinical Research Priority Program, University of Zurich.
Abstract (Originalsprache)
Human immunodeficiency virus type 1 (HIV-1) infection is treated with antiretroviral therapy (ART), usually consisting of 2–3 different drugs, referred to as combination ART (cART). Our recent randomized clinical trial comparing a switch to dolutegravir monotherapy with continuation of cART in early-treated individuals demonstrated sustained virological suppression over 48 weeks. Here, we characterize the longitudinal landscape of the HIV-1 reservoir in these participants, with particular attention to potential differences between treatment groups regarding evidence of evolution as a proxy for low-level replication. Near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing was applied to longitudinal peripheral blood mononuclear cell samples to assess proviral evolution and the potential emergence of drug resistance mutations (DRMs). Neither an increase in genetic distance nor diversity over time was detected in participants of both treatment groups. Single proviral analysis showed high proportions of defective proviruses and low DRM numbers. No evidence for evolution during dolutegravir monotherapy was found in these early-treated individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich.
- Institute of Medical Virology, University of Zurich, Switzerland.
ORCID-Profile: Lisa Jörimann, Marius Zeeb, Huldrych F Günthard
Förderung
- Swiss National Science Foundation
- Clinical Research Priority Program
- University of Zurich
Zitieren
APA
Jörimann, L., Tschumi, J., Zeeb, M., Leemann, C., Schenkel, C. D., Neumann, K., Chaudron, S. E., Zaheri, M., Frischknecht, P., Neuner-Jehle, N., Kuster, H., Braun, D. L., Grube, C., Kouyos, R., Metzner, K. J., Günthard, H. F., & Swiss HIV Cohort Study (SHCS) (2023). Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks. The Journal of Infectious Diseases, 228(7), 907-918. https://doi.org/10.1093/infdis/jiad292
Vancouver
Jörimann L, Tschumi J, Zeeb M, Leemann C, Schenkel CD, Neumann K, et al. Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks. The Journal of Infectious Diseases. 2023;228(7):907-918. doi:10.1093/infdis/jiad292
BibTeX
@article{Jrimann2023,
author = {Jörimann, Lisa and Tschumi, Jasmin and Zeeb, Marius and Leemann, Christine and Schenkel, Corinne D and Neumann, Kathrin and Chaudron, Sandra E and Zaheri, Maryam and Frischknecht, Paul and Neuner-Jehle, Nadia and Kuster, Herbert and Braun, Dominique L and Grube, Christina and Kouyos, Roger and Metzner, Karin J and Günthard, Huldrych F and Swiss HIV Cohort Study (SHCS), Swiss HIV Cohort Study (SHCS)},
title = {Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks},
journal = {The Journal of Infectious Diseases},
year = {2023},
volume = {228},
number = {7},
pages = {907--918},
doi = {10.1093/infdis/jiad292}
}
EUVIMED